| Assessment Status |
Full HTA submission received from Applicant |
| HTA ID |
23069 |
| Drug |
Birch bark extract |
| Brand |
Filsuvez® |
| Indication |
Treatment of partial thickness wounds associated with dystrophic and junctional epidermolysis bullosa (EB) in patients 6 months and older. |
| Rapid review commissioned |
10/11/2023 |
| Rapid review completed |
08/12/2023 |
| Rapid review outcome |
A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of birch bark extract compared with the current standard of care. |
| Full pharmacoeconomic assessment commissioned by HSE |
18/12/2023 |
| Pre-submission consultation with Applicant |
23/04/2024 |
| Full submission received from Applicant |
15/10/2024 |
